Lannett Approved for Generic Suboxone Sublingual Tabs

the generic tablets are indicated for the treatment of opioid dependence
the generic tablets are indicated for the treatment of opioid dependence

Lannett announced that the Food and Drug Administration (FDA) has approved Buprenorphine and Naloxone Sublingual Tablets, the generic version of Reckitt Benckiser's Suboxone Sublingual Tablets.

Buprenorphine and Naloxone Sublingual Tablets, a CIII controlled substance, is indicated for the treatment of opioid dependence. It combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu-opioid receptors and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally. 

Related Articles

Buprenorphine and Naloxone Sublingual Tablets was approved under a Risk Evaluation and Mitigation Strategy (REMS) and will be distributed according to the FDA and Drug Enforcement Administration (DEA) regulations governing CIII controlled substances. It will be available as 2mg/0.5mg and 8mg/2mg strength tablets. 

For more information visit Lannett.com.

Loading links....